ArticleNucleic acids research1991
Functional modularity in the SP6 kappa promoter.
Article in Nucleic acids research, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 19 citations in OpenAlex.
- IMGTVaccines · 2022Article
- Transcription factor AP-4 is a ligand for immunoglobulin-kappa promoter E-box elements.The Biochemical journal · 2001Article
- A defective Vkappa A2 allele in Navajos which may play a role in increased susceptibility to haemophilus influenzae type b disease.The Journal of clinical investigation · 1996Article
- Pentadecamer-binding proteins: definition of two independent protein-binding sites needed for functional activity.Molecular and cellular biology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The requirements of the SP6 kappa promoter for transcriptional activation were studied in nontransformed murine B lymphocytes stimulated with lipopolysaccharide. Three different DNA motifs, besides the TATA-box, were needed for restoration of transcriptional activation to the same magnitude as seen with the native SP6 kappa promoter. The decamer motif (TNCTTTGCAT) was found to induce transcription alone and point-mutation of this element reduced transcription to negligible levels, although the other two required elements were present. The penta-decamer element (TGCAG/CCTGTGNCCAG) did not stimulate transcription alone, but activated transcription synergistically in conjunction with the decamer motif. This synergism required the presence of a third pyrimidine rich element (CCCT) in the decamer 3' flanking sequence. The pyrimidine rich element could partly be substituted for by an E-box core motif (CANNTG) 3' of, but not by the kappa Y motif (CTTCCTTA) 5' of, the decamer. Proteins interacting specifically with the penta-decamer element were detected by band-shift assay. The decamer 3' flanking sequence of the SP6 kappa promoter was found to modify the binding of endogenous Oct2 isoforms to the decamer motif i B lymphocytes, but not in CHO cells transfected with various Oct2 isoforms. Thus, complex protein/DNA interactions can be observed in the SP6 kappa promoter which correlate functionally with a synergism in transcriptional activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.